CPHI (China Pharma Holdings, Inc.) Rega marang bathi mangsa ngarep

Government procurement in China is reducing generic drug margins, weakening the market position of China Pharma Holdings (CPHI). However, stable cash flow is maintained through legacy CNS medications. The mass production of anti-infective and antipsychotic drugs at the company's own plants is confirmed by the projected P/E ratio chart for China Pharma Holdings (CPHI), where the indicator settled at 0.00.
Rincian metrik lan analitis perusahaan China Pharma Holdings (CPHI)

This indicator compares the projected business value with the issuer's actual ability to generate cash flow for debt service, excluding subjective management forecasts. By analyzing the future P/E NTM of China Pharma Holdings (CPHI), an investor can see how the robotization of generic production and warehouse automation at China Pharma Holdings (CPHI) reduce costs, directly converting technological efficiency into the fundamental undervaluation or overvaluation of the asset.